Direkt zum Inhalt
Merck

30165

Sigma-Aldrich

Tirofiban

≥98.5% (HPLC)

Synonym(e):

(2S)-2-(Butylsulfonylamino)-3-{4-[4-(4-piperidyl)-butoxy}-phenylpropansäure, N-(Butylsulfonyl)-O-[4-(4-piperidinyl)-butyl]-L-tyrosin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C22H36N2O5S
CAS-Nummer:
Molekulargewicht:
440.60
Beilstein:
6182267
MDL-Nummer:
UNSPSC-Code:
12352106
PubChem Substanz-ID:
NACRES:
NA.25

Qualitätsniveau

Assay

≥98.5% (HPLC)

Form

powder

SMILES String

CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(O)=O

InChI

1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1

InChIKey

COKMIXFXJJXBQG-NRFANRHFSA-N

Angaben zum Gen

Anwendung


  • The efficacy and safety of continuous intravenous tirofiban for acute ischemic stroke patients treated by endovascular therapy: a meta-analysis.: This meta-analysis assesses the safety and efficacy of continuous intravenous tirofiban in patients undergoing endovascular therapy for acute ischemic stroke, showing promising results for improved outcomes (Wang et al., 2024).

  • Initial Experience with a New Self-Expanding Open-Cell Stent System with Antithrombotic Hydrophilic Polymer Coating (pEGASUS Stent) in the Treatment of Wide-Necked Intracranial Aneurysms.: This study reports on the initial use of a new stent system coated with tirofiban in treating intracranial aneurysms, demonstrating enhanced safety and efficacy (Boxberg et al., 2024).

Verpackung

Bottomless glass bottle. Contents are inside inserted fused cone.

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

dust mask type N95 (US), Eyeshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Veysel Ozan Tanık et al.
Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 28(2), 115-123 (2018-11-19)
In this study, we aimed to determine the predictive value of the CHA2DS2VASc score for acute stent thrombosis in patients with an ST elevation myocardial infarction treated with a primary percutaneous coronary intervention (pPCI). This was a retrospective study conducted
Volker Maus et al.
World neurosurgery, 111, e424-e433 (2017-12-27)
Acute dissecting aneurysms of the posterior circulation are a rare cause of subarachnoid hemorrhage. Established endovascular treatment options include parent artery occlusion and stent-assisted coiling, but appear to be associated with an increased risk of ischemic stroke. Vessel reconstruction with
Jan H Cornel et al.
The American journal of cardiology, 115(10), 1325-1332 (2015-03-18)
We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acute coronary syndromes who underwent PCI. In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
K J McClellan et al.
Drugs, 56(6), 1067-1080 (1999-01-08)
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. Adenosine diphosphate (ADP)-induced platelet aggregation returns to near-baseline levels within 4 to 8 hours
Marco Valgimigli et al.
JACC. Cardiovascular interventions, 5(3), 268-277 (2012-03-24)
The authors sought to compare the effect on inhibition of platelet aggregation (IPA) of prasugrel therapy versus tirofiban bolus with or without a post-bolus short drug infusion in ST-segment elevation myocardial infarction (STEMI) patients. The degree and rapidity of IPA

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.